Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 298

1.

Opioid dependency in pregnancy and length of stay for neonatal abstinence syndrome.

Pritham UA, Paul JA, Hayes MJ.

J Obstet Gynecol Neonatal Nurs. 2012 Mar;41(2):180-90. doi: 10.1111/j.1552-6909.2011.01330.x. Epub 2012 Feb 29.

2.

Prenatal buprenorphine versus methadone exposure and neonatal outcomes: systematic review and meta-analysis.

Brogly SB, Saia KA, Walley AY, Du HM, Sebastiani P.

Am J Epidemiol. 2014 Oct 1;180(7):673-86. doi: 10.1093/aje/kwu190. Epub 2014 Aug 22. Review.

PMID:
25150272
3.

Impact of treatment approach on maternal and neonatal outcome in pregnant opioid-maintained women.

Metz V, Jagsch R, Ebner N, Würzl J, Pribasnig A, Aschauer C, Fischer G.

Hum Psychopharmacol. 2011 Aug;26(6):412-21. doi: 10.1002/hup.1224. Epub 2011 Aug 8.

4.

Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data.

Debelak K, Morrone WR, O'Grady KE, Jones HE.

Am J Addict. 2013 May-Jun;22(3):252-4. doi: 10.1111/j.1521-0391.2012.12005.x.

PMID:
23617867
5.

Design considerations for point-of-care clinical trials comparing methadone and buprenorphine treatment for opioid dependence in pregnancy and for neonatal abstinence syndrome.

Winhusen T, Wilder C, Wexelblatt SL, Theobald J, Hall ES, Lewis D, Van Hook J, Marcotte M.

Contemp Clin Trials. 2014 Sep;39(1):158-65. doi: 10.1016/j.cct.2014.08.009. Epub 2014 Aug 23.

PMID:
25183042
6.

Neonatal abstinence syndrome after methadone or buprenorphine exposure.

Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, O'Grady KE, Selby P, Martin PR, Fischer G.

N Engl J Med. 2010 Dec 9;363(24):2320-31. doi: 10.1056/NEJMoa1005359.

7.

Randomized controlled trials in pregnancy: scientific and ethical aspects. Exposure to different opioid medications during pregnancy in an intra-individual comparison.

Unger A, Jagsch R, Jones H, Arria A, Leitich H, Rohrmeister K, Aschauer C, Winklbaur B, Bäwert A, Fischer G.

Addiction. 2011 Jul;106(7):1355-62. doi: 10.1111/j.1360-0443.2011.03440.x. Epub 2011 May 12.

8.

Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates.

Gaalema DE, Scott TL, Heil SH, Coyle MG, Kaltenbach K, Badger GJ, Arria AM, Stine SM, Martin PR, Jones HE.

Addiction. 2012 Nov;107 Suppl 1:53-62. doi: 10.1111/j.1360-0443.2012.04039.x.

9.

Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication.

Kaltenbach K, Holbrook AM, Coyle MG, Heil SH, Salisbury AL, Stine SM, Martin PR, Jones HE.

Addiction. 2012 Nov;107 Suppl 1:45-52. doi: 10.1111/j.1360-0443.2012.04038.x.

10.

Obstetrical and neonatal outcomes of methadone-maintained pregnant women: a canadian multisite cohort study.

Ordean A, Kahan M, Graves L, Abrahams R, Kim T.

J Obstet Gynaecol Can. 2015 Mar;37(3):252-257. doi: 10.1016/S1701-2163(15)30311-X.

PMID:
26001872
11.

Breastfeeding promotion for management of neonatal abstinence syndrome.

Pritham UA.

J Obstet Gynecol Neonatal Nurs. 2013 Sep-Oct;42(5):517-26. doi: 10.1111/1552-6909.12242. Epub 2013 Sep 4. Review.

PMID:
24020477
12.

Methadone and perinatal outcomes: a prospective cohort study.

Cleary BJ, Eogan M, O'Connell MP, Fahey T, Gallagher PJ, Clarke T, White MJ, McDermott C, O'Sullivan A, Carmody D, Gleeson J, Murphy DJ.

Addiction. 2012 Aug;107(8):1482-92. doi: 10.1111/j.1360-0443.2012.03844.x. Epub 2012 May 8.

PMID:
22340442
13.

Retrospective chart review comparing morphine and methadone in neonates treated for neonatal abstinence syndrome.

Young ME, Hager SJ, Spurlock D Jr.

Am J Health Syst Pharm. 2015 Dec 1;72(23 Suppl 3):S162-7. doi: 10.2146/sp150025.

PMID:
26582303
14.

Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy.

Jones HE, Dengler E, Garrison A, O'Grady KE, Seashore C, Horton E, Andringa K, Jansson LM, Thorp J.

Drug Alcohol Depend. 2014 Jan 1;134:414-417. doi: 10.1016/j.drugalcdep.2013.11.006. Epub 2013 Nov 16.

15.

Neonatal outcomes following in utero exposure to methadone or buprenorphine: a National Cohort Study of opioid-agonist treatment of Pregnant Women in Norway from 1996 to 2009.

Welle-Strand GK, Skurtveit S, Jones HE, Waal H, Bakstad B, Bjarkø L, Ravndal E.

Drug Alcohol Depend. 2013 Jan 1;127(1-3):200-6. doi: 10.1016/j.drugalcdep.2012.07.001. Epub 2012 Jul 25.

PMID:
22841456
16.

Time to initiation of treatment for neonatal abstinence syndrome in neonates exposed in utero to buprenorphine or methadone.

Gaalema DE, Heil SH, Badger GJ, Metayer JS, Johnston AM.

Drug Alcohol Depend. 2013 Nov 1;133(1):266-9. doi: 10.1016/j.drugalcdep.2013.06.004. Epub 2013 Jul 8.

17.

Breastfeeding rates and the relationship between breastfeeding and neonatal abstinence syndrome in women maintained on buprenorphine during pregnancy.

O'Connor AB, Collett A, Alto WA, O'Brien LM.

J Midwifery Womens Health. 2013 Jul-Aug;58(4):383-8. doi: 10.1111/jmwh.12009.

PMID:
23931660
18.

Buprenorphine and naloxone compared with methadone treatment in pregnancy.

Wiegand SL, Stringer EM, Stuebe AM, Jones H, Seashore C, Thorp J.

Obstet Gynecol. 2015 Feb;125(2):363-8. doi: 10.1097/AOG.0000000000000640.

PMID:
25569005
19.

Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.

Jones HE, Heil SH, Baewert A, Arria AM, Kaltenbach K, Martin PR, Coyle MG, Selby P, Stine SM, Fischer G.

Addiction. 2012 Nov;107 Suppl 1:5-27. doi: 10.1111/j.1360-0443.2012.04035.x. Review.

20.

Neonatal neurobehavior effects following buprenorphine versus methadone exposure.

Coyle MG, Salisbury AL, Lester BM, Jones HE, Lin H, Graf-Rohrmeister K, Fischer G.

Addiction. 2012 Nov;107 Suppl 1:63-73. doi: 10.1111/j.1360-0443.2012.04040.x.

Supplemental Content

Support Center